186 related articles for article (PubMed ID: 19605822)
1. Myelodysplastic/myeloproliferative neoplasms.
Foucar K
Am J Clin Pathol; 2009 Aug; 132(2):281-9. PubMed ID: 19605822
[TBL] [Abstract][Full Text] [Related]
2. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
3. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
4. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
5. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
6. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification.
Cannella L; Breccia M; Latagliata R; Frustaci A; Alimena G
Leuk Res; 2008 Mar; 32(3):514-6. PubMed ID: 17709138
[No Abstract] [Full Text] [Related]
8. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
9. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
10. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes.
Kuykendall AT; Tokumori FC; Komrokji RS
Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873
[TBL] [Abstract][Full Text] [Related]
11. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.
Leguit RJ; Orazi A; Kucine N; Kvasnicka HM; Gianelli U; Arber DA; Porwit A; Ponzoni M
Virchows Arch; 2022 Oct; 481(4):621-646. PubMed ID: 35819517
[TBL] [Abstract][Full Text] [Related]
12. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
13. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
Smith BN; Savona M; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
[TBL] [Abstract][Full Text] [Related]
14. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Mughal TI; Cross NC; Padron E; Tiu RV; Savona M; Malcovati L; Tibes R; Komrokji RS; Kiladjian JJ; Garcia-Manero G; Orazi A; Mesa R; Maciejewski JP; Fenaux P; Itzykson R; Mufti G; Solary E; List AF
Haematologica; 2015 Sep; 100(9):1117-30. PubMed ID: 26341525
[TBL] [Abstract][Full Text] [Related]
15. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
16. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
Padron E
Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742
[TBL] [Abstract][Full Text] [Related]
17. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
18. Mixed myeloproliferative and myelodysplastic disorders.
Emanuel PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):9-12. PubMed ID: 20425383
[TBL] [Abstract][Full Text] [Related]
19. NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.
Behnert A; Lee AG; Young EP; Breese MR; Leung SG; Behroozfard I; Maruffi M; Sweet-Cordero EA; Dvorak CC; Chu J; Stieglitz E
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e808-e811. PubMed ID: 32815876
[TBL] [Abstract][Full Text] [Related]
20. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]